| Pengana International Equities Limited (PIA) ORDINARY FULLY PAID |
Financials |
$282 |
Update - Notification of buy-back - PIA
|
28 Aug 2025 9:00AM |
$1.280 |
$1.095 |
fallen by
14.45%
|
|
| Beamtree Holdings Limited (BMT) ORDINARY FULLY PAID |
Health Care |
$38 |
FY25 Annual Report
|
28 Aug 2025 8:59AM |
$0.270 |
$0.130 |
fallen by
51.85%
|
|
| Micro-X Limited (MX1) ORDINARY FULLY PAID |
Health Care |
$20 |
MX1 - 2025 Appendix 4G and Corporate Governance Statement
|
28 Aug 2025 8:59AM |
$0.079 |
$0.026 |
fallen by
67.09%
|
|
| AnteoTech Limited (ADO) ORDINARY FULLY PAID |
Materials |
$62 |
Full Year Results and Business Update Presentation
|
28 Aug 2025 8:59AM |
$0.022 |
$0.019 |
fallen by
13.64%
|
|
ADO - Price-sensitive ASX Announcement
Full Release
Key Points
- AnteoTech focuses on battery and life sciences markets.
- Patented products include Anteo X and Ultranode for battery technologies.
- Life Sciences division enhances test performance with AnteoBind.
- Sales revenue continues to grow with strategic market expansion.
- Expansion in the USA, South Korea, India, and Europe is ongoing.
- Strategic partnerships targeted globally, including potential entry into China.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AnteoTech Limited (ADO) ORDINARY FULLY PAID |
Materials |
$62 |
Full Year Results and Business Update Presentation
|
28 Aug 2025 8:59AM |
$0.022 |
$0.019 |
fallen by
13.64%
|
|
ADO - Price-sensitive ASX Announcement
Full Release
Key Points
- AnteoTech presented its Full Year Results and Business Update for 2025.
- Focus on advanced battery and life sciences markets.
- Developed high-silicon anode formulations Ultranode and Anteo X binder product.
- Strategic partnerships with Wyon and Black Diamond Structures.
- Five-year supply agreement with Serum Institute for AnteoBind product.
- Continuous sales growth in product sales, licensing fees, and contract services.
- Expansion plans in the USA, South Korea, India, and potentially China.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Micro-X Limited (MX1) ORDINARY FULLY PAID |
Health Care |
$20 |
MX1 - 2025 Appendix 4E and Annual Report
|
28 Aug 2025 8:59AM |
$0.079 |
$0.026 |
fallen by
67.09%
|
|
MX1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Micro-X Limited reported a significant loss, highlighting financial challenges.
- Revenue was primarily from grant income rather than sales, indicating reliance on external funding.
- Substantial expenses were reported in research and development, employee benefits, and corporate costs.
- The company is focusing on the commercialisation of the Felixâ„¢ System, a key strategic goal.
- Technological advancements and innovation in the reproductive biotechnology sector are ongoing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Micro-X Limited (MX1) ORDINARY FULLY PAID |
Health Care |
$20 |
MX1 - 2025 Appendix 4E and Annual Report
|
28 Aug 2025 8:59AM |
$0.079 |
$0.026 |
fallen by
67.09%
|
|
MX1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Micro-X Limited focused on the design, development, manufacturing, and commercialisation of carbon nanotube-based X-ray products.
- The company executed a supply agreement for Rover Plus systems with a major US healthcare provider.
- Revenue decreased to $13.053M in 2025 from $15.222M in 2024.
- Loss after income tax was $13.895M compared to $9.765M in 2024.
- The company discontinued its Argus product line, resulting in a $1.5M inventory write-off.
- Micro-X is pursuing funded development for a Full Body CT scanner under a contract with ARPA-H worth up to $25M.
- Strategic partnerships include a collaboration with Billion Prima for a baggage scanner product.
- Revenue from engineering contract services increased, with major contributions from the US Department of Homeland Security and ARPA-H.
- The group's net assets as of 30 June 2025 were $7.548M.
- The company is implementing a Sustainability Strategy aligned with several international frameworks.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bailador Technology Investments Limited (BTI) ORDINARY FULLY PAID |
Financials |
$147 |
Notice of Annual General Meeting/Proxy Form
|
28 Aug 2025 8:58AM |
$1.250 |
$0.970 |
fallen by
22.40%
|
|
| Beamtree Holdings Limited (BMT) ORDINARY FULLY PAID |
Health Care |
$38 |
Preliminary Final Report
|
28 Aug 2025 8:58AM |
$0.270 |
$0.130 |
fallen by
51.85%
|
|
BMT - Price-sensitive ASX Announcement
Full Release
Key Points
- Beamtree Holdings Limited reported an increase in revenue but also an increase in loss for the year.
- No dividends were paid, recommended, or declared during the current financial period.
- The financial statements have been audited with an unmodified conclusion.
- Net tangible assets per ordinary security increased from 0.6 cents to 0.8 cents.
- Recurring revenue from licenses, subscriptions, and usage fees increased, while non-recurring analytical services revenue decreased.
- Total operating expenses slightly increased, leading to a higher loss before and after tax compared to the previous year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Beamtree Holdings Limited (BMT) ORDINARY FULLY PAID |
Health Care |
$38 |
Preliminary Final Report
|
28 Aug 2025 8:58AM |
$0.270 |
$0.130 |
fallen by
51.85%
|
|
BMT - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenues from ordinary activities up 4% to AUD 28.6 million.
- Total revenue and other income increased by 3% to AUD 28.6 million.
- Loss attributable to owners increased by 21% to AUD 6.159 million.
- No dividends were declared during the financial period.
- Net tangible assets per ordinary security improved from 0.6 cents to 0.8 cents.
- Financial statements were audited and received an unmodified conclusion.
- EBITDA was negative AUD 664,000 due to employment and operating costs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Noxopharm Limited (NOX) ORDINARY FULLY PAID |
Health Care |
$28 |
Sofra technology platform presentation
|
28 Aug 2025 8:58AM |
$0.115 |
$0.090 |
fallen by
21.74%
|
|
| Gemlife Communities Group (GLF) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$1,829 |
1H FY25 results exceed Prospectus Forecast
|
28 Aug 2025 8:58AM |
$4.650 |
$4.810 |
risen by
3.44%
|
|
| Gemlife Communities Group (GLF) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$1,829 |
1H FY25 Results Presentation
|
28 Aug 2025 8:58AM |
$4.650 |
$4.810 |
risen by
3.44%
|
|
| Australian Foundation Investment Company Limited (AFI) ORDINARY FULLY PAID |
Financials |
$8,418 |
Update - Notification of buy-back - AFI
|
28 Aug 2025 8:58AM |
$7.350 |
$6.860 |
fallen by
6.67%
|
|
| Orora Limited (ORA) ORDINARY FULLY PAID |
Materials |
$1,829 |
Update - Notification of buy-back - ORA
|
28 Aug 2025 8:58AM |
$2.180 |
$1.493 |
fallen by
31.54%
|
|
| Lithium Plus Minerals Ltd (LPM) ORDINARY FULLY PAID |
Materials |
$21 |
DRX: Proposed sale of Clermont Gold Project
|
28 Aug 2025 8:58AM |
$0.078 |
$0.135 |
risen by
73.08%
|
|
| Diatreme Resources Limited (DRX) ORDINARY FULLY PAID |
Materials |
$65 |
Proposed sale of Clermont Gold Project
|
28 Aug 2025 8:58AM |
$0.020 |
$0.013 |
fallen by
35%
|
|
DRX - Price-sensitive ASX Announcement
Full Release
Key Points
- Diatreme to divest Clermont Gold Project to Moonlight Resources.
- Moonlight targeting rapid resource delineation and IPO on ASX.
- Diatreme to receive A$3.25 million in shares and A$250,000 in cash.
- Diatreme to hold 17.1% to 19.9% stake in Moonlight post-IPO.
- Conditions for sale include due diligence and regulatory approvals.
- Diatreme focuses on silica assets, transitioning Clermont to Moonlight.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Diatreme Resources Limited (DRX) ORDINARY FULLY PAID |
Materials |
$65 |
Proposed sale of Clermont Gold Project
|
28 Aug 2025 8:58AM |
$0.020 |
$0.013 |
fallen by
35%
|
|
DRX - Price-sensitive ASX Announcement
Full Release
Key Points
- Diatreme sells Clermont Gold Project to Moonlight Resources.
- Transaction involves shares and performance rights valued at A$3.25 million plus A$250,000 in cash.
- Moonlight aims for rapid resource delineation and ASX listing by end of 2025.
- Diatreme retains significant shareholder status in Moonlight.
- Transaction subject to due diligence and regulatory approvals.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gemlife Communities Group (GLF) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$1,829 |
1H FY25 Appendix 4D and Financial Reports
|
28 Aug 2025 8:57AM |
$4.650 |
$4.810 |
risen by
3.44%
|
|
| DXN Limited (DXN) ORDINARY FULLY PAID |
Information Technology |
$142 |
Appendix 4E and Annual Report
|
28 Aug 2025 8:57AM |
$0.065 |
$0.385 |
risen by
492.31%
|
|
DXN - Price-sensitive ASX Announcement
Full Release
Key Points
- DXN Limited reported a comprehensive loss of AUD 2.31 million for the year.
- Revenue increased to AUD 16.03 million, primarily from data centre manufacturing.
- Major expenses included depreciation, amortization, and employee benefits.
- Total assets amounted to AUD 16.15 million; liabilities were AUD 11.23 million.
- Net assets stood at AUD 4.92 million as of 30 June 2025.
- Share-based payments and options issuance were significant during the year.
- Liquidity management and financial risk strategies were emphasized.
- Changes in key management personnel were noted in the report.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| DXN Limited (DXN) ORDINARY FULLY PAID |
Information Technology |
$142 |
Appendix 4E and Annual Report
|
28 Aug 2025 8:57AM |
$0.065 |
$0.385 |
risen by
492.31%
|
|
DXN - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 49% to $16.03 million.
- Net loss after tax was $2.31 million.
- EBITDA of $5,769 and Underlying EBITDA of $814,526.
- No dividends were paid or declared during the year.
- Expansion into Data Centre as a Service (DCaaS) division.
- Geographical expansion prioritized in the APAC region.
- The financial statements were audited with an unmodified opinion.
- Focus on targeting high-growth segments in digital infrastructure.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Amotiv Limited (AOV) ORDINARY FULLY PAID |
Consumer Discretionary |
$841 |
Update - Notification of buy-back - AOV
|
28 Aug 2025 8:57AM |
$9.710 |
$6.280 |
fallen by
35.32%
|
|
| Eagers Automotive Limited (APE) ORDINARY FULLY PAID |
Consumer Discretionary |
$6,300 |
2025 Half Year Results Presentation
|
28 Aug 2025 8:57AM |
$22.550 |
$22.310 |
fallen by
1.06%
|
|
| Eagers Automotive Limited (APE) ORDINARY FULLY PAID |
Consumer Discretionary |
$6,300 |
2025 Half Year Results Announcement
|
28 Aug 2025 8:56AM |
$22.550 |
$22.310 |
fallen by
1.06%
|
|
| AMCIL Limited (AMH) ORDINARY FULLY PAID |
Financials |
$286 |
Update - Notification of buy-back - AMH
|
28 Aug 2025 8:56AM |
$1.080 |
$0.910 |
fallen by
15.74%
|
|